ATAI is pursuing rapid-acting mental health treatments with key late-stage catalysts ahead, but its outlook still hinges on ...
A single dose of the LSD-based therapy DT120 produced rapid antidepressant effects that remained significant through 12 weeks in a pivotal phase 3 trial of major depressive disorder.
By Kamal Choudhury June 22 (Reuters) - Definium Therapeutics said a single dose of its LSD-based experimental pill ...
Results for Definium Therapeutics psychedelic candidate for major depressive disorder “exceeded expectations,” according to ...
A single dose of DT120 orally disintegrating tablets significantly improved depression severity in adults with major depressive disorder compared with placebo.
Definium Therapeutics (NASDAQ:DFTX) shares climbed about 53% on Monday after the biopharmaceutical company reported positive ...
Dosages for the Phase IIa programme were selected following the successful completion of the double-blind stage of Beckley Psytech’s Phase I study earlier this year, which showed that BPL-003 was well ...
TORONTO--(BUSINESS WIRE)--Biomind Labs Inc. (“Biomind Labs” or the “Company”) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotech company focused on developing the next generation of ...
Compass Pathways plc is poised to start the first ever phase III trial of the psychedelic drug psilocybin, after getting U.S. FDA backing for a study in treatment-resistant depression. The phase III, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results